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Abstract
Background: The transmembrane protein c-kit is a receptor tyrosine kinase (KIT) and KIT is
expressed in solid tumors and hematological malignancies such as gastrointestinal stromal tumor
(GIST), small-cell lung cancer and chronic myelogenous leukemia (CML). KIT plays a critical role in
cell proliferation and differentiation and represents a logical therapeutic target in GIST and CML.
In pancreatic cancer, c-kit expression has been observed by immunohistochemical techniques. In
this study, we examined the influence of c-kit expression on proliferation and invasion using five
pancreatic cancer cell lines. In addition, the inhibitory effect of imatinib mesylate on stem cell factor
(SCF)-induced proliferation and invasion was evaluated. Finally, we also analyzed KIT and SCF
expression in pancreatic cancer tissues using immunohistochemistry and correlated the results
with clinical features.
Results: RT-PCR revealed that two pancreatic cancer cell lines, PANC-1 and SW1990, expressed
c-kit mRNA. By Western blot analysis, c-kit protein was also present in those lines. In KIT-positive
pancreatic cancer cell lines, proliferation and invasion were significantly enhanced by addition of
SCF. In contrast, SCF did not enhance proliferation and invasion in the three KIT-negative lines
(BxPC-3, Capan-2 and MIA PaCa-2). 5 µM imatinib mesylate significantly inhibited SCF-enhanced
proliferation to the same extent compared with the control. Similarly, SCF-enhanced invasive
ability was significantly inhibited by 5 µM imatinib mesylate. KIT was expressed in 16 of 42 clinical
specimens by immunohistochemistry, and KIT expression was significantly related to venous
system invasion. Furthermore, patients expressing both KIT and SCF had a somewhat lower
survival.
Conclusion: Our results demonstrated that the SCF-KIT pathway enhanced the proliferation and
invasiveness in KIT-positive pancreatic cancer cell lines and that the enhanced proliferation and
invasion were inhibited by imatinib mesylate. We propose that inhibitors of c-kit tyrosine kinase
receptor have the potential to slow the progression of KIT-positive pancreatic cancers.
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Background
The transmembrane protein c-kit  is a receptor tyrosine
kinase (KIT) which is closely related to other receptors
including platelet-derived growth factor receptor and
macrophage growth factor receptor [1,2]. The primary lig-
and for KIT is stem cell factor (SCF) which is also known
as mast cell growth factor, steel factor and kit ligand [3-6].
Binding of SCF to KIT causes dimerization, autophospho-
rylation and signal transduction [7]. The SCF-KIT signal-
ing system supports the proliferation, differentiation and
survival of KIT-expressing cells, such as hematopoietic
progenitors, mast cells, melanocytes, germ cells and cells
of Cajal [8-12]. KIT is expressed in normal cells and also
in solid tumors and hematological malignancies such as
gastrointestinal stromal tumor (GIST) [13], small-cell
lung cancer [14], colorectal cancer [15], Ewing's tumor
[16], chronic myelogenous leukemia (CML) [17], neurob-
lastoma [18] and mast cell leukemia [19]. On the other
hand, breast cancer and thyroid cancer are associated with
loss of KIT expression [20,21]. Mutations are observed in
c-kit  in some malignant diseases such as GIST [13],
chronic myelogenous leukemia [17] and mast cell leuke-
mia [22]. Mutation of c-kit can result in activation of the
receptor in the absence of ligand. Certain c-kit mutations
are associated with more frequent relapse and decreased
survival [23]. Thus, it is apparent that KIT plays a critical
role in cell proliferation and differentiation [24,25] and
represents a logical therapeutic target in GIST, CML and
other diseases [26]. For example, c-kit  tyrosine kinase
receptor is targeted by imatinib mesylate (STI571, Glivec)
[27].
In pancreatic cancer, c-kit expression has been observed by
immunohistochemical techniques [28-30]. Furthermore,
SCF may play a role in growth regulation in the normal
pancreas [31]. However, at this time, the contribution of
c-kit receptor to in vitro models of pancreatic cancer is not
known. In this study, we examined the influence of c-kit
expression on proliferation and invasion using five pan-
creatic cancer cell lines. In addition, the inhibitory effect
of imatinib mesylate on SCF-induced proliferation and
invasion was evaluated. Finally, we also analyzed KIT and
SCF expression in pancreatic cancer tissues using immu-
nohistochemistry and correlated the results with clinical
features.
Results
Expression of c-kit in pancreatic cancer cell lines
RT-PCR revealed that two pancreatic cancer cell lines,
PANC-1 and SW1990, expressed c-kit mRNA (Fig. 1A). By
Western blot analysis, c-kit protein was also present in
those lines (Fig. 1B). Neither c-kit mRNA nor protein was
detected in the other three pancreatic cancer cell lines,
BxPC-3, Capan-2 and MIA PaCa-2. Thus, Western blot
analysis confirms the PT-PCR results.
Effect of SCF on pancreatic cancer cell proliferation
Figure 2 shows the effect of SCF on proliferation of KIT-
positive and KIT-negative pancreatic cancer cell lines. In
the two KIT-positive cell lines (PANC-1 and SW1990),
proliferation was significantly enhanced by KIT ligand
SCF when the concentration exceeded 1 ng/mL (Fig. 2A).
In contrast, SCF did not enhance proliferation in the three
KIT-negative lines (BxPC-3, Capan-2 and MIA PaCa-2)
(Fig. 2B).
Effect of SCF on pancreatic cancer cell invasion
Figures 3A and 3B show the effect of SCF on cell invasive-
ness in the five pancreatic cancer cell lines. SCF enhanced
the invasive ability in the two KIT-positive cell lines (Fig.
3A). On the other hand, the invasive potential was not
enhanced by SCF in the three KIT-negative cancer cell
lines (Fig. 3B).
c-kit mRNA and protein expression in pancreatic cancer cell  lines Figure 1
c-kit mRNA and protein expression in pancreatic 
cancer cell lines. (A) c-kit mRNA expression in pancreatic 
cancer cell lines was detected by RT-PCR. As a control, β-
actin expression was also examined. (B) c-kit protein expres-
sion in pancreatic cancer cell lines was confirmed by West-
ern blot analysis. Reprobing with an anti-β-actin antibody 
served as a control.Molecular Cancer 2006, 5:46 http://www.molecular-cancer.com/content/5/1/46
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Inhibitory effect of imatinib mesylate on proliferation and 
invasion
We asked whether imatinib mesylate might inhibit KIT-
stimulated proliferative and invasive activities of the two
KIT-positive pancreatic cancer cell lines (PANC-1 and
SW1990). As shown in Fig. 4, 5 µM imatinib mesylate sig-
nificantly inhibited SCF-enhanced proliferation to the
level shown by nonstimulated control. Similarly, SCF-
enhanced invasive ability was significantly inhibited by 5
µM imatinib mesylate treatment of PANC-1 and SW1990
(Fig. 5).
Immunohistochemistry
KIT and SCF expression were evaluated in 42 patients with
confirmed invasive ductal carcinoma of the pancreas. Fig.
6A shows one example of a KIT-positive pancreatic cancer
cells and Fig. 6B shows one example of a SCF-positive
pancreatic cancer cells. Table 1 shows the clinical and
pathological characteristics of the patients. Pancreatic can-
cer cells expressed KIT in 16 of the 42 cases (38.1%). Char-
acteristics of the patients, such as gender, age, location of
the tumor, TNM stage and cancer cell differentiation, were
not significantly different between the KIT-positive and
KIT-negative groups. In lymph node metastases, lym-
phatic system invasion and intrapancreatic neural inva-
Effect of SCF on invasiveness of pancreatic cancer cell lines Figure 3
Effect of SCF on invasiveness of pancreatic cancer 
cell lines. (A) KIT-positive pancreatic cancer cell lines and 
(B) KIT-negative cell lines. Cell invasion was evaluated using 
the Matrigel assay. SCF enhanced the invasion in c-kit-posi-
tive pancreatic cancer cell lines. Statistical analysis was per-
formed by one-way ANOVA with the Dunnett test for 
PANC-1 and SW1990 and by the Student t test for BxPC-3, 
Capan-2 and MIA PaCa-2. Bars indicate the SD, *, p < 0.01 
compared with control.
Effect of SCF on proliferation of pancreatic cancer cell lines Figure 2
Effect of SCF on proliferation of pancreatic cancer 
cell lines. (A) KIT-positive pancreatic cancer cell lines, and 
(B) KIT-negative cell lines. Cell proliferation was determined 
using the WST-1 assay. SCF stimulated the proliferation of 
KIT-positive pancreatic cancer cell lines. Statistical analysis 
was performed by one-way ANOVA with the Dunnett test. 
Bars indicate the SD, *, p < 0.01 compared with control.Molecular Cancer 2006, 5:46 http://www.molecular-cancer.com/content/5/1/46
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sion, there were no significant differences between the
two groups. But, the expression of KIT was correlated with
venous system invasion (p = 0.046). Pancreatic cancer
cells expressed SCF in fourteen KIT-positive specimens. In
fact, fourteen specimens co-expressed KIT and SCF. Fur-
thermore, KIT-positive specimens expressed SCF more fre-
quently compared to KIT-negative specimens (p = 0.002).
Concerning patient survival, KIT expression was not sig-
nificantly correlated (Fig. 7A), but the cases co-expressing
KIT and SCF had a tendency toward lower survival than
others (Fig 7B). However, the difference was not statisti-
cally significant. The median follow-up time was 14.8
months after surgery.
Discussion
In this study, we examined the relationship between c-kit
expression and the malignant potential of pancreatic can-
cer cells. Thus, we demonstrated the influence of c-kit
expression on proliferation and invasion of pancreatic
cancer cell lines in vitro. In addition, we analyzed the rela-
tionship between KIT and SCF expression in pancreatic
cancer tissues and examined clinical features and progno-
sis.
First, c-kit expression was examined in five pancreatic can-
cer cell lines. It was ascertained that two of the cell lines,
PANC-1 and SW1990, expressed c-kit mRNA and protein
by RT-PCR and Western blot analysis. Based on those
results, we defined these two pancreatic cancer cell lines as
KIT-positive. Next, we stimulated those lines with SCF to
investigate the differences in proliferative responses
between KIT-positive and KIT-negative cell lines. In the
two KIT-positive cell lines, proliferation was significantly
enhanced by SCF at concentrations above 1 ng/mL. On
the other hand, SCF did not enhance proliferation of KIT-
negative cancer cell lines. Results from the invasion
(Matrigel) assay were consistent with the proliferation
assay. Namely, the invasive ability of KIT-positive pancre-
atic cancer cell lines was significantly enhanced by addi-
tion of SCF at concentrations above 1 ng/mL. The fact that
KIT activation induces proliferation or invasion in vitro
was also reported in lung cancer and colorectal cancer
[15,32,33]. In this study, 1 ng/mL SCF significantly
enhanced proliferation and invasion. Because the human
in vivo level of SCF in serum is between 1 ng/mL and 3 ng/
mL [34-36], serum SCF concentration may be high
enough to stimulate the proliferation and invasion of
pancreatic cancer cells in vivo. Recently, it was shown that
the existence of mast cells which showed immunoreactiv-
ity for SCF was ascertained in pancreatic cancer [31]. Our
studies indicate that KIT expression by pancreatic cancer
cells may have functional significance. Thus, we propose
that serum SCF and SCF secreted from mast cells could
contribute to in vivo tumor progression of KIT-positive
pancreatic cancer.
In pancreatic cancer specimens, c-kit receptor was report-
edly expressed in 6.1% based on immunohistochemical
techniques [28]. On the other hand, two other studies
Inhibitory effect of imatinib mesylate on SCF-induced invasive  ability Figure 5
Inhibitory effect of imatinib mesylate on SCF-
induced invasive ability. Cells were incubated without 
either SCF or imatinib mesylate (control, white columns), or 
with 10 ng/mL SCF (black columns) or with 10 ng/mL SCF 
and 5 µM imatinib mesylate (horizontal striped columns) for 
24 hours. Statistical analysis was performed by one-way 
ANOVA with the SNK test. Bars indicate the SD *, p < 0.05 
compared with control; **, p < 0.01 compared with control; 
#, p < 0.01 compared with SCF.
Inhibitory effect of imatinib mesylate on SCF-enhanced prolif- eration in pancreatic cancer cell lines Figure 4
Inhibitory effect of imatinib mesylate on SCF-
enhanced proliferation in pancreatic cancer cell lines. 
Cells were incubated without either SCF or imatinib 
mesylate (control, white columns), or with 10 ng/mL SCF 
(black columns), or with 10 ng/mL SCF and 5 µM imatinib 
mesylate (horizontal striped columns) for 72 hours and pro-
liferation was measured by WST-1 assay. Statistical analysis 
was performed by one-way ANOVA with the SNK test. Bars 
indicate the SD, *, p < 0.05 compared with control; #, p < 
0.01 compared with SCF 10 ng/mL.Molecular Cancer 2006, 5:46 http://www.molecular-cancer.com/content/5/1/46
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from the same department reported that about 80% of
pancreatic cancers expressed KIT [29,30]. In the present
study, KIT was expressed in 38% of pancreatic cancer spec-
imens (16 of 42 patients) by immunohistochemistry. In
the report which concluded that 6.1% of pancreatic cancer
expressed KIT, antigen retrieval was not performed. Thus,
the percentage expressing KIT may be erroneously low. As
to the studies reporting about 80% KIT expression, anti-
gen retrieval was done using urea. On the other hand, we
used Target Retrieval Solution High pH (DAKO, Copen-
hagen, Denmark) for antigen retrieval according to the
antibody manufacturer's instruction. The difference
between the methods relating to antigen retrieval may
contribute to the differences in KIT-positive ratio.
In this study, clinicopathological findings associated with
venous system invasion were significantly more severe in
the KIT-positive group than in the KIT-negative group.
Interestingly, KIT activation has been linked to vascular
endothelial growth factor (VEGF) expression in GIST [37].
In addition, it was reported that VEGF expression was sig-
nificantly correlated with venous invasion in gastric can-
cer [38]. From these facts, we suppose that KIT induced
VEGF expression may have relationship with venous sys-
tem invasion in pancreatic cancer. As to prognosis, in
small-cell lung cancer, patients with KIT expression had a
significant tendency toward lower survival than did KIT-
negative patients [14]. Concerning pancreatic cancer, two
studies reported that KIT-positive patients had a tendency
toward lower survival than did c-kit-negative patients, but
the differences were not significant [29,30]. Those results
were confirmed here, as the difference in prognosis
between KIT-positive and KIT-negative patients was not
significant.
With regard to expression of SCF, pancreatic cancer speci-
mens were evaluated for simultaneous expression with
KIT. Co-expression of KIT and SCF has been reported in
small-cell lung cancer, and in those diseases, autocrine
pathways are suggested [39,40]. In our immunohisto-
chemical study, 14 pancreatic cancer specimens co-
expressed KIT and SCF, and the proportion of SCF-posi-
tive specimens was significantly larger in KIT-positive
specimens than in KIT-negative ones. Patients co-express-
ing KIT and SCF had a tendency toward lower survival
than others. Thus, autocrine pathways may play impor-
tant roles in the evolution of malignant disease in the pan-
creas.
Recently, drugs which selectively inhibit tyrosine kinase
receptors have been developed [24-26]. The goal is tumor-
specific disruption of cell proliferation and differentia-
tion. Targeted receptors include epidermal growth factor
receptor and vascular endothelial growth factor receptor
[41,42]. Because c-kit  tyrosine kinase receptor has an
important role in tumor progression, the KIT inhibitor
imatinib mesylate is being explored for therapeutic effi-
cacy [27]. Imatinib mesylate was initially designed to
inhibit Bcr/Abl kinase which is present in 95% of patients
with CML [43]. Later, it was found that imatinib mesylate
also inhibited the c-kit tyrosine kinase receptor [44]. Imat-
inib mesylate is used for the therapy of GIST and leukemia
and contributes to improvement of the prognosis,
response ratio and quality of life [45]. In this study, we
assessed the inhibitory effect of imatinib mesylate on pro-
liferation and invasion of pancreatic cancer cells. In leuke-
mia patients, imatinib mesylate plasma concentrations
were in the range of 0.17 µM – 5.68 µM when 25 – 600
mg of the drug was administered per day [46]. We admin-
istered 5 µM imatinib mesylate to pancreatic cancer cell
lines, and the concentration was within the in vivo range
of plasma. In KIT-positive pancreatic cancer cell lines, 5
µM imatinib mesylate significantly inhibited SCF-
enhanced proliferation to the level shown by nonstimu-
Table 1: Clinical and pathological characteristics of patients according to the expression of KIT.
KIT expression (overall n = 42)
KIT positive (n = 16) KIT negative (n = 26) p-value
Gender Male/Female 10/6 18/8 NS
Age (year) 64.5 ± 7.2 66.3 ± 10.8 NS
TNM stage I/II/III/IV/unclear 2/3/8/3/0 5/4/12/4/1 NS
Tumor location Head/Body, Tail 10/6 22/4 NS
Cancer cell differentiation W/Mo/P/Mu 3/11/1/1 11/10/5/0 NS
SCF Positive/Negative 14/2 10/16 0.002
Lymph node metastasis Positive/Negative 14/2 21/5 NS
Intrapancreatic neural invasion ne2, 3/ne0, 1 14/2 17/9 NS
Lymphatic system invasion ly2, 3/ly0, 1 9/7 13/13 NS
Venous system invasion v2, 3/v0, 1 10/6 8/18 0.046
NS = not significant. W = well differentiated adenocarcinoma; Mo = moderately differentiated adenocarcinoma; P = papillary adenocarcinoma; Mu 
= mucinous carcinoma. Values of age are given mean ± SD. The p-values were obtained using the Mann-Whitney U-test.Molecular Cancer 2006, 5:46 http://www.molecular-cancer.com/content/5/1/46
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lated control. Imatinib mesylate similarly reduced inva-
sive potential. As to the therapy of pancreatic cancer,
gemcitabine is used as the standard chemotherapy now,
and therapies combining gemcitabine with other drugs
have been explored [47]. For KIT-positive pancreatic can-
cers, KIT inhibitors could block the ligand-dependent sig-
naling pathway. Thus, we propose that a KIT inhibitor
could be used with gemcitabine, or used as a second
choice when the pancreatic cancer is resistant to gemcitab-
ine.
Conclusion
KIT was expressed in 38% of pancreatic cancer patients
and expression correlated with the degree of venous sys-
tem invasion. Furthermore, KIT-positive specimens
expressed significantly more SCF than did KIT-negative
patients and patients expressing both KIT and SCF had a
tendency toward lower survival. In vitro, we demonstrated
that the SCF-KIT pathway enhanced the proliferation and
invasiveness in KIT-positive pancreatic cancer cell lines
and that the enhanced proliferation and invasion were
inhibited by imatinib mesylate. We propose that inhibi-
tors of c-kit tyrosine kinase receptor have the potential to
slow the progression of KIT-positive pancreatic cancers.
Thus, clinical exploration of such inhibitors in the setting
of pancreatic cancer should be pursued.
Cumulative survival and expression of KIT and SCF Figure 7
Cumulative survival and expression of KIT and SCF. 
Cumulative survival curve in (A) KIT-positive patients and (B) 
KIT-positive and SCF-positive patients by Kaplan-Meier anal-
ysis. Statistical significance was analyzed by the log-rank test.
Immunohistochemical detection of KIT and SCF expression  in pancreatic cancer Figure 6
Immunohistochemical detection of KIT and SCF 
expression in pancreatic cancer. (A) KIT-positive pan-
creatic cancer cells (× 200). (B) SCF-positive pancreatic can-
cer cells (× 200).Molecular Cancer 2006, 5:46 http://www.molecular-cancer.com/content/5/1/46
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Methods
Cell culture
Five human pancreatic cancer cell lines (SW1990, PANC-
1, MIA PaCa-2, Capan2 and BxPC3) were obtained from
the American Type Culture Collection (Rockville, MD).
SW1990, PANC-1 and MIA PaCa-2 were maintained in
Dulbecco's modified Eagle's medium (Sigma Chemical
Co., St. Louis, MO) supplemented with 10% fetal bovine
serum. Capan2 was maintained in McCoy's medium sup-
plemented with 10% fetal bovine serum. BxPC3 was
maintained in RPMI-1640 medium (Sigma Chemical Co.,
St. Louis, Mo) supplemented with 10% fetal bovine
serum. All cells were incubated at 37°C in a humidified
atmosphere of 5% CO2 in air.
Reagents and antibodies
Recombinant human SCF was purchased from R&D Sys-
tems (Abingdon, UK). For Western blot analysis, rabbit
polyclonal anti-KIT antibody was obtained from Med. &
Biological Laboratories (Nagoya, Japan) and rabbit mon-
oclonal anti-β-actin antibody was obtained from Cell Sig-
naling Technology (Beverly, MA). For
immunohistochemistry, rabbit polyclonal anti-KIT anti-
body and rabbit polyclonal anti-SCF antibody were pur-
chased from Immuno-Biological Laboratories Co., Ltd.
(Gunma, Japan). KIT inhibitor imatinib mesylate was
kindly provided by Novartis Pharma AG (Basel, Switzer-
land).
RT-PCR analysis
Total RNA was extracted from five pancreatic cancer cell
lines using Isogen Kits (Nippon Gene Tokyo, Japan), and
quantities determined spectrophotometrically. Total RNA
aliquots (1 µg) were pretreated with Dnase I (Boehringer
Mannheim, Germany) for 20 minutes at room tempera-
ture, denatured at 70°C for 10 minutes, chilled on ice,
and then reverse-transcribed into cDNA in a reaction mix-
ture containing 10 mmol/L dithiothreitol, 0.5 mmol/L
dNTPs, first standard buffer, and 1U Superscript II (Invit-
rogen, San Diego, CA) at 42°C for 60 minutes. Reactions
were terminated by heating at 72°C for 10 minutes. Reac-
tion mixture aliquots (1 µL) were used as templates for
PCR. The following primers for c-kit were used: forward 5'-
gcccacaatagattggtattt-3' and reverse 5'-agcatcttta-
cagcgacagtc-3'. The PCR product size was 570 bp. The PCR
conditions were as follows: denaturation at 94°C for 4
minutes, annealing at 51°C for 1 minute, extension at
72°C for 1 minute, followed by 34 cycles of denaturation
at 94°C for 1 minute, annealing at 51°C for 1 minute, and
extension at 72°C for 1 minute. The final extension was at
72°C for 7 minutes. The PCR products were separated and
detected using ethidium-bromide stained 1.5% agarose
gels.
Western blot analysis
Total cell lysates from confluent cultures were prepared
using ice-cold radioimmunoprecipitation assay (RIPA)
buffer containing leupeptin, aprotinin, and pepstein A.
Protein concentration of the cell lysates was measured
using a BCA protein assay kit (Pierce, Rockford, IL). 30 µg
of protein from cell lysates were separated on 7.5% SDS-
PAGE and transferred to a PVDF membrane. The mem-
brane was incubated in blocking buffer for 2 hours at
room temperature. The blocking buffer consisted of 5%
nonfat dry milk in Tris buffered saline containing 0.1%
Tween 20 (TBS-T). After washing the membrane with TBS-
T, the membrane was incubated with rabbit anti-KIT anti-
body diluted 1:1000 overnight at 4°C. Then, the mem-
brane was washed with TBS-T, and subjected to
horseradish peroxidase-conjugated anti-rabbit immu-
noglobulin (DAKO, Copenhagen, Denmark) diluted
1:2000 as a second antibody for 1 hour at room tempera-
ture. Protein-antibody complexes were visualized with an
ECL Western blotting detection and analysis system
(Amersham Biosciences, Buckinghamshire, UK). The
membrane was washed and stripped using Restore West-
ern Blot Stripping Buffer (Pierce, Rockford, IL) and β-actin
was detected using rabbit anti-β-actin antibody by the
same method.
Proliferation assay
To examine the influence of SCF on cell proliferation, we
used the Premix WST-1 Cell Proliferation Assay System
(TAKARA BIO INC., Shiga, Japan). Five human pancreatic
cancer cell lines were seeded at a density of 3 × 103/100 µL
in 96-well plates and allowed to adhere for 24 hours.
Then, cultures were refed with fresh media containing var-
ious concentration of SCF. After 72 hours incubation, 10
µL WST-1 reagent was added to each well and the trays
were incubated for 2 hours at 37°C, at which point the
absorbance was measured using a microplate reader with
a test wave length of 450 nm and a reference wavelength
of 690 nm. In studies of imatinib mesylate, cells were
incubated with SCF (10 ng/mL) alone or with both SCF
(10 ng/mL) and imatinib mesylate (5 µM). In controls,
cells were incubated without either SCF or imatinib
mesylate. After 72 hours incubation, the inhibitory effect
was evaluated using the WST-1 Cell Proliferation Assay
System
Invasion assay
The in vitro invasive potential of human pancreatic cancer
cells was determined using BioCoat Matrigel Invasion
Chambers (Becton Dickinson, Bedford, MA). This system
is separated by a PET membrane coated with Matrigel
Matrix such that only invasive cells can migrate through
the membrane to the reverse side. After rehydration for 2
hours in a humidified incubator at 37°C with 5% CO2,
cells were suspended in medium containing 10% FBS,Molecular Cancer 2006, 5:46 http://www.molecular-cancer.com/content/5/1/46
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placed in the upper chamber at a concentration of 1 × 105
cells/chamber and incubated for 24 hours at 37°C with
5% CO2 with various concentrations of SCF. After 24
hours incubation, noninvasive cells were removed from
the upper surface of the membrane by scrubbing. The cells
on the reverse side of the membrane were fixed with 70%
ethanol, stained with Giemsa solution, and counted
under a microscope at 200 × magnification. We also inves-
tigated the inhibitory effect of imatinib mesylate on SCF-
mediated invasion using the same method. Namely, cells
were incubated with SCF (10 ng/mL) or with both SCF
(10 ng/mL) and imatinib mesylate (5 µM) for 24 hours.
For controls, cells were incubated without either SCF or
imatinib mesylate.
Immunohistochemistry
Forty-two patients diagnosed with invasive ductal adeno-
carcinoma of the pancreas underwent pancreatic resec-
tions at Nagoya City University Hospital between April
1989 and March 2005 and were included in this study.
Specimens were fixed in 10% formalin and then embed-
ded in paraffin. Specimens were sectioned into 3 µm-thick
slices and the sections were deparaffinized. Next, the sec-
tions were subjected to autoclave treatment in Target
Retrieval Solution High pH (DAKO, Copenhagen, Den-
mark) for 20 minutes at 95°C for KIT antigen retrieval.
For SCF, the sections were subjected to autoclave treat-
ment in 0.01 M sodium citrate buffer (pH 6.0) for 20 min-
utes at 95°C. Then, all sections were immersed in
blocking reagent (Block Ace, Dainippon Pharma Co., Ltd.,
Osaka, Japan) for 10 minutes to reduce non-specific bind-
ing. After removal of excess serum, the sections were incu-
bated with primary antibodies against KIT or SCF (diluted
1:50) for 60 minutes at room temperature. After rinsing in
phosphate buffered saline (PBS), the sections were treated
with horseradish peroxidase-labeled anti-rabbit immu-
noglobulin (DAKO, Copenhagen, Denmark) as a second
antibody for 30 minutes at room temperature. The perox-
idase reaction was visualized by incubating the sections
with 0.02% 3.3'-diaminobenzidine tetrahydrochloride in
0.05 M Tris buffer (pH 7.6) with 0.01% hydrogen perox-
ide, followed by hematoxylin counter staining. As a nega-
tive control, staining was also performed using normal
mouse immunoglobulin G in place of the primary anti-
body. Results of each immunohistochemical staining
were evaluated as follows. The intensity of tissue staining
was graded semiquantitatively on a four-point scale (-, +,
++, +++), and the proportion of cells stained was assessed
on a four-tier scale (1. 0%-15%; 2. 15%-50%; 3. 50%-
85%; and 4. 85%-100% cells stained). The cases were clas-
sified into positive group and negative group by the inten-
sity and proportion of immunostained cancer cells for KIT
and SCF. Cases where the immunostaining intensity was
more than ++ and the proportion was more than 2 were
defined as positive group. When venous system invasion
was evaluated, we classified v0 and v1 as the slight group,
and v2 and v3 as the severe group. We assessed the rela-
tionship between KIT expression and two groups of
venous invasion. With regard to intrapancreatic neural
invasion and lymphatic system invasion, evaluations were
conducted in the same way as venous invasion.
Statistical analysis
All experiments were performed in triplicate. Results are
expressed as means ± SD (standard deviation). Multiple
group comparisons were performed by one-way ANOVA
with a post hoc test for subsequent individual group com-
parison. Differences between two samples were analyzed
by an unpaired t test. Survival analyses were calculated by
using the Kaplan-Meier method and the differences in sur-
vival among subjects were compared with the log-rank
test. The Mann-Whitney U-test was used to compare the
immunohistochemical characteristics. Differences were
considered statistically significant at p < 0.05.
Abbreviations
GIST, gastrointestinal stromal tumor; CML, chronic myel-
ogenous leukaemia; SCF, stem cell factor; VEGF vascular
endothelial growth factor; SDS-PAGE, SDS-polyacryla-
mide gel electrophoresis; TBS, tris buffered saline; PBS,
phosphate buffered saline.
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